Leonard Valentino: Excited to Share The New Perspectives on Hemophilic Arthropathy
Leonard Valentino, Former President and CEO of NBDF, President of WFH USA, recenlty shared a post on LinkedIn about a recent article he and Yesim Dargaud co-authored, published in Haematologica, adding:
”I’m excited to share our latest review in the journal Haematologica: ‘Mechanisms of Blood-Induced Joint Disease in Hemophilia and Potential Novel Targets for Interventions.’
For decades, hemophilic arthropathy has been viewed primarily as a consequence of recurrent joint bleeding. In this review, we explore a broader perspective: hemarthrosis is the initiating event, but iron-driven biological processes are what ultimately fuel chronic joint degeneration.
Our analysis integrates historical observations with emerging insights from molecular biology and single-cell genomics to propose an updated model of blood-induced joint disease.
We highlight how iron deposition following bleeding triggers oxidative stress, inflammation, synovial remodeling, vascular changes, and cartilage injury that can persist long after the bleeding episode itself.
Several emerging mechanisms deserve particular attention:
- Iron-driven oxidative stress as a central driver of synovial and cartilage pathology.
- Endothelial ferroptosis and vascular remodeling as potential contributors to ongoing joint vulnerability and re-bleeding.
- The iRhom2/ADAM17/TNF-α pathway as a key mediator of synovial inflammation and bone loss.
- Activated mast cells and endothelial–fibroblast crosstalk as newly recognized components of the hemophilic joint microenvironment.
- The TNXB–AKT pathway as a potentially important cartilage-protective mechanism that may offer new opportunities for chondroprotection.
The central message of our review is straightforward: preventing bleeding remains essential, but preventing arthropathy may require targeting the biological consequences of blood exposure within the joint.
Looking ahead, therapeutic strategies directed at iron handling, oxidative stress, ferroptosis, inflammatory signaling, fibroblast reprogramming, and cartilage survival pathways may complement modern hemostatic therapies and help preserve lifelong joint health.
I am grateful to my co-author, Dr. Yesim Dargaud, for her collaboration on this work and look forward to the discussions that these concepts may stimulate across the hemophilia community.”
Title: Mechanisms of blood-induced joint disease in hemophilia and potential novel targets for interventions
Authors: Leonard Valentino, Yesim Dargaud
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 18, 2026, 17:08Irem Karaman Sebin: ASH 2026 Changes a Key Concept in Iron Deficiency
-
Sep 18, 2026, 16:51Adarsh Krishnan Sundara Rajan: Is VTE the Most Underdiagnosed Critical Threat in Modern Healthcare?
-
Sep 18, 2026, 16:19CRISPR and Hemophilia: The Next Frontier of In Vivo Gene Editing
-
Sep 18, 2026, 16:13Christian Irsara: PF4 Immunothrombosis Following Natural Adenovirus Infection
-
Sep 18, 2026, 16:10Leo Nicolai։ The Spleen Emerges as a Key Regulator of Thromboinflammation
-
Sep 18, 2026, 16:05Targeting Factor XI to Reduce Thrombosis Without Compromising Hemostasis – ISTH
-
Sep 18, 2026, 15:54Swapnil Pawar: Why Aren’t We Using Cryopreserved Platelets Everywhere Yet?
-
Sep 18, 2026, 15:37Abdul Mannan: Evaluating Longitudinal Platelet Trends Beyond Standard Reference Intervals
-
Sep 18, 2026, 15:30Peter A. Everts։ Platelet Phenotype May Hold the Key to More Consistent PRP Therapy